2 weeks Ago By Defense World Staff
Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX – Get Free Report ) has been given a consensus rating of “Moderate Buy” by the thirty brokerages that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eighteen have given a buy rating to the company.
The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $499.12. A number of research analysts have recently commented on the stock.
Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. Morgan Stanley lifted their price target on Vertex Pharmaceuticals from $473.
00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Piper Sandler upped their price objective on Vertex Pharmaceuticals from $500.
00 to $535.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $600.
00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, October 21st. Finally, Canaccord Genuity Group boosted their target price on Vertex Pharmaceuticals from $361.00 to $408.
00 and gave the stock a “sell” rating in a report on Wednesday, November 6th. View Our Latest Analysis on Vertex Pharmaceuticals Insider Buying and Selling at Vertex Pharmaceuticals Institutional Investors Weigh In On Vertex Pharmaceuticals Institutional investors and hedge funds have recently made changes to their positions in the business. Northwest Investment Counselors LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter worth $25,000.
Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $27,000. GHP Investment Advisors Inc. bought a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $29,000.
Stephens Consulting LLC acquired a new position in shares of Vertex Pharmaceuticals during the second quarter worth approximately $31,000. Finally, Founders Capital Management lifted its holdings in shares of Vertex Pharmaceuticals by 50.0% in the 2nd quarter.
Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock worth $35,000 after purchasing an additional 25 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.
Vertex Pharmaceuticals Stock Performance VRTX opened at $483.96 on Tuesday. The business’s 50-day simple moving average is $476.
13 and its 200 day simple moving average is $470.48. Vertex Pharmaceuticals has a 52-week low of $341.
90 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.
01, a quick ratio of 2.20 and a current ratio of 2.47.
The firm has a market capitalization of $124.63 billion, a PE ratio of -248.55 and a beta of 0.
39. Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.
38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77.
The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion.
Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%.
The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.
67 EPS. As a group, sell-side analysts expect that Vertex Pharmaceuticals will post -1.82 earnings per share for the current fiscal year.
About Vertex Pharmaceuticals ( Get Free Report Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. See Also Five stocks we like better than Vertex Pharmaceuticals About the Markup Calculator 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick What is the Hang Seng index? Mouse Rising: The Iger Investment Pays Off for Disney Investors ESG Stocks, What Investors Should Know Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
